Effects of serum from breast cancer surgery patients receiving perioperative dexmedetomidine on breast cancer cell malignancy: A prospective randomized controlled trial

Adrenergic receptors (ARs) have gained attention for their involvement in breast cancer (BC) progression. Dexmedetomidine, a selective α(2)‐AR agonist, has been reported to increase the malignancy of BC cells in vitro or stimulate tumor growth in mice. However, clinical evidence is lacking. Clinical...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Yan, Sun, Jiaxin, Wu, Tong, Lu, Xiaoying, Du, Yueyao, Duan, Hongwei, Yu, Weifeng, Su, Diansan, Lu, Jinsong, Tian, Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6912063/
https://www.ncbi.nlm.nih.gov/pubmed/31663690
http://dx.doi.org/10.1002/cam4.2654

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6912063/
https://www.ncbi.nlm.nih.gov/pubmed/31663690
http://dx.doi.org/10.1002/cam4.2654

Ejemplares similares